Investigational Drug Details
| Drug ID: | D312 |
| Drug Name: | Thalidomide |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB01041 |
| DrugBank Description: | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem] |
| PubChem ID: | 5426 |
| CasNo: | 50-35-1 |
| Repositioning for NAFLD: | Yes |
| SMILES: | O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12 |
| Structure: |
|
| InChiKey: | UEJJHQNACJXSKW-UHFFFAOYSA-N |
| Molecular Weight: | 258.2295 |
| DrugBank Targets: | Protein cereblon; DNA; alpha1-acid glycoprotein |
| DrugBank MoA: | In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor. |
| DrugBank Pharmacology: | Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans. |
| DrugBank Indication: | For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L1953 | NCT02058160 | PHASE3 | COMPLETED | YES | 2014-01 | 2017-05-09 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|